title: Derivatives of Dexanabinol. I. Water-soluble salts of glycinate esters.
abstract: OBJECTIVE
  Glycinate ester-type water soluble derivatives of dexanabinol (HU-211) (1) a non-psychotropic cannabinoid with potential use in the treatment of brain damage were synthesized and evaluated as prodrugs or congeners.
  
  
  METHODS
  Conventional procedures were used for the synthesis of the novel derivatives. Stability studies in water and blood (rat, dog, human) were performed by HPLC; NMDA receptor binding was determined by radio ligand [3H] MK-801-displacement; the neuroprotection and neurotoxicity studies were performed in cortical cell cultures.
  
  
  RESULTS
  Glycinate (3), dimethyl- and diethylamine (5, 6), trimethyl- and triethyl- ammonium (7, 8) acetates of 1 were synthesized. All compounds were relatively soluble and stable in water. The quaternary ammonium salt-type derivatives rapidly hydrolyzed to the parent drug in various types of blood including human. In vitro activity studies indicated that the novel derivatives possess NMDA receptor binding properties. The neuroprotecting properties manifested by some of the new derivatives were associated with very low neuronal cell toxicity and are credited to parent compound released by hydrolysis during the experiments rather than to intrinsic activity.
  
  
  CONCLUSIONS
  Compounds 7 and 8 are promising water-soluble pro-drug candidates for 1; the glycinate ester 3 might be used as an active analog.
authors.affiliation: Pharmos Corporation, Alachua, Florida 32615, USA.
authors.forename: E
authors.initials: E
authors.lastname: Pop
authors.forename: Z Z
authors.initials: ZZ
authors.lastname: Liu
authors.forename: M E
authors.initials: ME
authors.lastname: Brewster
authors.forename: Y
authors.initials: Y
authors.lastname: Barenholz
authors.forename: V
authors.initials: V
authors.lastname: Korablyov
authors.forename: R
authors.initials: R
authors.lastname: Mechoulam
authors.forename: V
authors.initials: V
authors.lastname: Nadler
authors.forename: A
authors.initials: A
authors.lastname: Biegon
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D004285:Dogs; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000097:blood / Q000138:chemical synthesis / Q000494:pharmacology; D004355:Drug Stability; D004952:Esters; D006801:Humans; D006868:Hydrolysis; D015394:Molecular Structure; D018696:Neuroprotective Agents / Q000097:blood / Q000138:chemical synthesis / Q000494:pharmacology*; D011355:Prodrugs / Q000138:chemical synthesis / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014867:Water
chemical_list: D004952:Esters; D018696:Neuroprotective Agents; D011355:Prodrugs; D014867:Water; D013759:Dronabinol; C062018:HU 211